Get the Stockscreener App
317.84
14.66%
41.40
Praxis Precision Medicines Inc stock is traded at $317.84, with a volume of 389.54K.
It is up +14.66% in the last 24 hours and down -5.88% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
See More
Previous Close:
$276.44
Open:
$289.2
24h Volume:
389.54K
Relative Volume:
0.79
Market Cap:
$8.83B
Revenue:
$7.46M
Net Income/Loss:
$-303.27M
P/E Ratio:
-23.60
EPS:
-13.4668
Net Cash Flow:
$-249.12M
1W Performance:
+7.57%
1M Performance:
-5.88%
6M Performance:
+498.05%
1Y Performance:
+736.98%
1-Day Range:
$279.27
$318.66
1-Week Range:
$271.94
$318.00
52-Week Range:
$26.70
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
316.92 | 7.70B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
445.29 | 112.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
769.90 | 79.21B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
723.77 | 43.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.75 | 41.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.00 | 33.05B | 606.42M | -1.28B | -997.58M | -6.403 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-02-26 | Initiated | Wells Fargo | Equal Weight |
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today? - MSN
FDA Prioritizes Review of Praxis Precision's (PRAX) Drug Applica - GuruFocus
Praxis Precision Medicines Gets FDA Priority Review for Relutrigine - marketscreener.com
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs - bitget.com
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vanguard subsidiaries disaggregate holdings; Praxis (PRAX) shows 0 shares reported - Stock Titan
Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN
Praxis Precision Medicines (NASDAQ:PRAX) Raised to Strong-Buy at Truist Financial - MarketBeat
(PRAX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings - AOL.com
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - AOL.com
Aug Swings: Is Praxis Precision Medicines Inc forming bullish engulfing patterns2026 Reactions & Reliable Momentum Entry Alerts - baoquankhu1.vn
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline - AOL.com
5AM Venture Divests Entire Praxis Precision Medicines Position | February 2026 FilingNews and Statistics - IndexBox
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit - Yahoo Finance
Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization? - Yahoo Finance
Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway - Insider Monkey
PRAX PE Ratio & Valuation, Is PRAX Overvalued - Intellectia AI
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - AOL.com
Algert Global LLC Increases Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Cormorant Sells $9.31M in Praxis Shares, Holding Remains Top Position | 2026 UpdateNews and Statistics - IndexBox
This biotech stock, which has surged by 700%, remains one of the leading holdings even after a $9.3 million sale in the previous quarter. - Bitget
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool
HighVista Strategies LLC Has $5.04 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (PRAX) Is Down 5.4% After Major Institutional Buying and FDA FilingsHas The Bull Case Changed? - simplywall.st
Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? - Yahoo Finance
Praxis FDA Filings Shift Focus From Pipeline Promise To Potential Revenue - Yahoo Finance
PRAX Technical Analysis & Stock Price Forecast - Intellectia AI
Praxis Precision Medicines, Inc. $PRAX Shares Sold by B Group Inc. - MarketBeat
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year - AOL.com
A Look At Praxis Precision Medicines (PRAX) Valuation After New Driehaus Investment And Recent FDA Filings - simplywall.st
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Biohaven Ltd. (BHVN) and Siemens Healthineers AG (OtherSEMHF) - The Globe and Mail
Liquidity Mapping Around (PRAX) Price Events - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), BillionToOne, Inc. Class A (BLLN) and Praxis Precision Medicines (PRAX) - The Globe and Mail
BTIG Maintains Buy on Praxis Precision Medicines (PRAX) March 2026 - Meyka
BTIG reiterates Buy on Praxis Precision Medicines stock at $843 By Investing.com - Investing.com Canada
BTIG reiterates Buy on Praxis Precision Medicines stock at $843 - Investing.com
Vanguard Group Inc. Increases Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines Stock Drops After Culper Research Reveals Short Position - MSN
Praxis Precision Medicines, Inc. $PRAX Shares Bought by Rafferty Asset Management LLC - MarketBeat
Praxis Precision Medicines, Inc. $PRAX Shares Sold by TD Asset Management Inc - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):